Susie Lisa
Senior Vice President of Investor Relations
We will get began. Thanks very a lot to everybody right here within the room for locating us regardless of locked doorways and escalators and difficult room places. We actually respect it. Clearly, a really, very thrilling ASN assembly general, and I believe, significantly, for Vertex Prescribed drugs. So very, very glad that you simply all might be with us tonight for our kidney program updates on the American Society of Nephrology Kidney Week 2026.
I just do wish to undergo the agenda briefly. Reshma will kick us off with some remarks about our R&D technique and our applications, give a fast portfolio overview. Then I’ve the pleasure of introducing to a lot of you, I believe, for the primary time, Dr. Akinlolu Ojo from the College of Kansas, who will focus on the latest AMPLIFIED knowledge and our AMKD program with inaxaplin after which we’ll hand it over to Dr. Richard Lafayette, whom you all know properly, and he’ll focus on the information launch this morning within the New England Journal of Drugs about povetacicept in IgAN. After which we’ll have time in your questions. We’ll try to preserve it actually punchy. We do have a tough cease proper at 7:00 p.m. and once more, thanks for becoming a member of us. Please word that we are going to be making forward-looking statements, and we ask you to seek the advice of all of our SEC filings to debate the chance components.
